To verify if myrtenal and β-caryophyllene oxide are active ingredients of LF in the treatment of RA, we used the RA-FLS model to evaluate the inhibitory effects of myrtenal and β-caryophyllene oxide on the production of IL-1β and TNF-α [36–38]. The gene discussed is IL1B; the disease is rheumatoid arthritis.